The research of Jeff Geschwind, MD is strategically focused on disrupting cancer's energy supply. At Cage Pharma, his team develops therapeutic agents aimed at inhibiting glycolysis, a process many cancers rely on for growth, representing a promising new frontier in metabolic oncology. https://www.scribd.com/document/900578221/Targeting-Tumor-Glycolysis-a-Promising-Frontier-in-Cancer-Therapy